NCT07376382
Not yet recruiting
Phase 3
A Randomized, Open-label, Multicenter, Phase III Clinical Trial to Evaluate the Safety and Efficacy of SYS6010 in Combination With Osimertinib in Patients With EGFR-mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.0 sites450 target enrollmentStarted: March 3, 2026Last updated:
Overview
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrollment
- 450
- Primary Endpoint
- Progression Free Survival(PFS) evaluated by IRC
Overview
Brief Summary
This study is a randomized, open-label, multicenter Phase III clinical trial evaluating patients with EGFR-mutant locally advanced or metastatic NSCLC. The Phase III study is planned to enroll approximately 450 participants, who will be randomized in a 1:1 ratio into the following groups:
Experimental group: SYS6010 + Osimertinib Control group: Osimertinib
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 18 \~ 75 (inclusive) years old, regardless of gender;
- •Patients with pathologically confirmed locally advanced or metastatic NSCLC, including: patients with stage IIIB or IIIC based on AJCC staging version 8 who are not suitable for surgical resection or radical chemoradiotherapy, or patients with stage IV NSCLC. For the dose escalation phase, patients must have EGFR-mutant locally advanced or metastatic NSCLC that has failed previous standard therapy, and for the dose selection phase and phase III study, patients must have EGFR-mutant locally advanced or metastatic NSCLC, which has not received EGFR-TKIs or other systemic therapy before. Patients who have received adjuvant/neoadjuvant chemotherapy may be included if disease progression occurred at least 6 months after completing treatment;
- •Carry at least one EGFR-sensitive mutation (ex19del or L858R, which can be combined with other EGFR mutations). EGFR mutation: Stage Ib: can be enrolled based on previous test results. Phase III: Take the test results of the central laboratory as the admission group;
- •At least one measurable lesion confirmed by CT or MRI, as defined by RECIST v1.1 criteria;
- •ECOG performance status score 0-1;
- •Expected survival ≥ 3 months;
- •Major organ function meets the relevant laboratory test standards for hematology, renal function, liver function, and coagulation within 7 days prior to treatment;
- •Women of childbearing age had a negative blood pregnancy test within 7 days prior to the first use of study drug. Participants must agree to take effective contraceptive measures from signing the informed consent form to 7 months after the last dose, during which women are non-breastfeeding and men avoid sperm donation;
- •Volunteer to participate in this clinical study, understand the study procedures, and be able to sign a written informed consent form.
Exclusion Criteria
- •Patients with meningeal metastases, brainstem metastases, spinal cord metastases and/or compression, or active CNS metastases;
- •History of other malignant tumors within 3 years prior to the first use of study drug, except for the following conditions: cured skin basal cell or squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, or cervical carcinoma in situ, etc.;
- •Known allergies to SYS6010 or any ingredient of Osimertinib, or to humanized monoclonal antibodies;
- •Adverse events caused by prior anti-tumor therapy that have not resolved to ≤ Grade 1 (as per NCI-CTCAE v6.0), except for Grade 2 alopecia or peripheral neuropathy deemed by the investigator not to pose a safety risk;
- •Use of any of the medications or treatments within the specified washout period (prior to first dose of study drug)
- •History of serious cardiovascular or cerebrovascular conditions within 6 months prior to the first dose, including but not limited to:Severe arrhythmias (e.g., ventricular arrhythmias requiring clinical intervention, third-degree atrioventricular block, QTcF \> 470 ms) (Fridericia formula: QTcF = QT/RR0.33, RR = 60/heart rate). Myocardial infarction, unstable angina, aortic dissection, angioplasty, or coronary artery bypass surgery. NYHA class II or higher heart failure with LVEF \< 50%.Stroke or other grade ≥ 3 cardiovascular/cerebrovascular events. pulmonary embolism.
- •Patients who have a history of ILD/non-infectious pneumonitis treated with corticosteroids in the past, currently have ILD/non-infectious pneumonitis, for whom imaging examinations at screening cannot rule out ILD/non-infectious pneumonitis, or whose pulmonary function test indicates severe ventilatory dysfunction and/or decreased diffusion capacity;
- •Severe infection within 4 weeks prior to the first dose, such as bacteremia requiring hospitalization, severe pneumonia, or active pulmonary tuberculosis; Active systemic infections requiring antibiotics within 2 weeks prior to administration;
- •Currently suffering from a skin condition requiring oral or vein administration;
- •Participants with active autoimmune disease or a history of autoimmune disease (e.g., ulcerative colitis or Crohn's disease) are excluded from the study. However, participants with the following conditions may be considered eligible for further screening: those with well-controlled type 1 diabetes, well-controlled hypothyroidism requiring only hormone replacement therapy, skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia), or diseases unlikely to relapse even when exposed to external triggers;
Arms & Interventions
SYS6010 combination
Experimental
SYS6010 + Osimertinib
Intervention: SYS6010 (Drug)
SYS6010 combination
Experimental
SYS6010 + Osimertinib
Intervention: Osimertinib (Drug)
Osimertinib
Active Comparator
Osimertinib
Intervention: Osimertinib (Drug)
Outcomes
Primary Outcomes
Progression Free Survival(PFS) evaluated by IRC
Time Frame: Up to 3.5 years
PFS is defined as the time from the date of randomization to the first documentation of PD as assessed by investigator per RECIST v.1.1, or death due to any cause, whichever occurs earlier.
Secondary Outcomes
- Progression Free Survival(PFS) evaluated by investigator(Up to 2.5 years)
- Overall survival (OS)(Up to 2.5 years)
- Objective Response Rate (ORR)(Up to 2.5 years)
- Duration of Response (DOR)(Up to 2.5 years)
- Disease Control Rate (DCR)(Up to 2.5 years)
- Incidence of adverse events(Up to 2.5 years)
- Incidence of Anti-Drug Antibody (ADA)(Up to 2.5 years)
- Blood concentration of SYS6010(Up to 2.5 years)
Investigators
Similar Trials
Recruiting
Phase 3
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07311694Jiangsu HengRui Medicine Co., Ltd.370
Not yet recruiting
Phase 3
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNCT07382687Fudan University248
Recruiting
Phase 1
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF MutationsNCT07288580Shanghai Euhearing Therapeutics Co., Ltd30
Not yet recruiting
Phase 2
SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaNCT07374549CSPC Megalith Biopharmaceutical Co.,Ltd.100
Completed
Phase 3
A Phase III Clinical Trial Evaluating the Efficacy and Safety of TriThien Duoc Capsules in Grade II Internal Haemorrhoids Patients With Bleeding Compared to Diosmin.NCT07369635Hanoi Medical University172